Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Long-Term Safety and Efficacy of Systemic DT-DEC01 Cell Therapy in Non-Ambulatory Duchenne Muscular Dystrophy Patients: a 24-Month Clinical Evaluation.

Stem cell reviews and reports·2025
Same author

Principles of Endoscopic Surveillance of Extrapapillary Duodenal Lesions in Familial Adenomatous Polyposis: A 14-Year Single-Center Observation.

Cancers·2025
Same author

Application of Human Epineural Patch (hEP) as a Novel Strategy for Nerve Protection and Enhancement of Regeneration After Nerve Crush Injury.

Biomedicines·2025
Same author

Protective Effect of the Human Epineural Patch Application after Sciatic Nerve Crush Injury Followed by Nerve Transection and End-to-End Repair.

Archivum immunologiae et therapiae experimentalis·2025
Same author

Mechanisms of Chimeric Cell Therapy in Duchenne Muscular Dystrophy.

Biomedicines·2024
Same author

Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy.

Stem cell reviews and reports·2024

相关实验视频

Updated: Jun 9, 2025

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.4K

开发用于杜氏肌肉发育不良症的先进化学细胞疗法.

Katarzyna Budzynska1, Katarzyna T Bozyk1, Klaudia Jarosinska1

  • 1Dystrogen Therapeutics Technology Polska sp. z o.o., 00-777 Warsaw, Poland.

International journal of molecular sciences
|October 26, 2024
PubMed
概括
此摘要是机器生成的。

研究人员优化了一种新的细胞融合协议,用于杜氏肌肉发育不良症 (DMD) 治疗. 该协议增强了表达氨酸的化学细胞 (DEC) 的产生,为DMD患者提供了潜在的新疗法.

关键词:
DEC疗法是一种治疗方法.杜申尼肌肉发育不良症 杜申尼肌肉发育不良症先进疗法的药物治疗产品.细胞融合是细胞的融合.双氨酸表达化学 (DEC) 细胞

更多相关视频

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.4K
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.0K

相关实验视频

Last Updated: Jun 9, 2025

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.4K
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

2.4K
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.0K

科学领域:

  • 再生医学是一种再生医学.
  • 细胞生物学 细胞生物学
  • 遗传学 遗传学是一种遗传学.

背景情况:

  • 杜琴肌肉发育不良 (DMD) 是一种致命的X关联疾病,导致肌肉逐渐退化.
  • 目前对DMD的治疗方法有限,没有确定的治疗方法.
  • 之前的研究表明,氨酸表达化学 (DEC) 细胞在治疗DMD方面具有潜力.

研究的目的:

  • 优化聚乙烯糖醇 (PEG) 介导的聚变协议,用于生成人类DEC细胞.
  • 确定影响细胞融合过程的有效性和可行性的关键因素.
  • 建立一个强大的方法来创建DEC细胞作为潜在的高级治疗药物 (ATMP) 治疗DMD.

主要方法:

  • 来自正常,无血缘关系的捐赠者的人类肌细胞被用于融合实验.
  • 优化过程评估了包括肌细胞通道数,PKH染色功效,MIX中的细胞比率和PEG施用时间在内的因素.
  • 评估了PEG融合后的细胞活力,以确保安全性和有效性.

主要成果:

  • 观察到PKH染色所使用的细胞数量与染色功效之间存在相关性.
  • 单染色肌细胞和PEG施用时间的比率显著影响了融合效率.
  • 髓细胞通道数没有与融合功效的相关性.

结论:

  • 该研究成功优化了PEG介导的融合协议,用于制造人类DEC细胞.
  • 这种优化的协议为产生用于治疗应用的DEC细胞提供了一种可重复的方法.
  • 优化的DEC细胞生成过程将DEC定位为一个有前途的新型高级治疗药物 (ATMP) 用于杜氏肌肉衰竭治疗.